Rituximab - PDFSEARCH.IO - Document Search Engine

Rituximab
Results: 190

#	Item
141	U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may Add to Reading List Source URL: www.fda.gov Language: English Rituximab Modafinil Adverse effect Progressive multifocal leukoencephalopathy Food and Drug Administration JC virus MedWatch Thrombocytopenia Lamotrigine Medicine Health Pharmacology
142	MRD in Clinical Trials (NAIG) Add to Reading List Source URL: www.fda.gov Language: English End point of clinical trials Progression-free survival Chemistry Bendamustine Rituximab Medicine Leukemia Minimal residual disease
143	HIGHLIGHTS OF PRESCRIBING INFORMATION These hig hlights do not include all the informatio n nee ded to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. • Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2013-09-27 15:15:31 Viruses HBsAg Alemtuzumab Ofatumumab Infusion pump Rituximab Nitazoxanide Medicine Pharmacology Hepatitis B
144	SPECIAL AUTHORIZATION REQUEST RHEUMATOID ARTHRITIS Fax requests to[removed]OR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 HIGH-COST DRUG PATIENT APPLICATION ALSO REQUIRED PRIOR TO C Add to Reading List Source URL: www.gov.pe.ca Language: English - Date: 2013-05-17 08:06:12 Immunology Rheumatoid arthritis Disease-modifying antirheumatic drug Leflunomide Rituximab Infliximab Hydroxychloroquine Abatacept TNF inhibitor Medicine Pharmacology Immunosuppressants
145	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA. Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2012-11-16 15:17:23 Biology Certolizumab pegol Anakinra Rheumatoid arthritis Etanercept Rituximab Latent tuberculosis Tumor necrosis factor-alpha Tuberculosis treatment Medicine Immunosuppressants Pharmacology
146	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIA® safely and effectively. See full prescribing information for CIMZIA. Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2012-08-03 11:03:50 Biology Certolizumab pegol Rheumatoid arthritis Anakinra Rituximab Etanercept Tumor necrosis factor-alpha Tuberculosis treatment Latent tuberculosis Medicine Immunosuppressants Pharmacology
147	GAZYVATM (obinutuzumab) label Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2014-07-01 15:10:48 Hepatitis B HBsAg Rituximab Treprostinil Medicine Chemotherapy Oncology
148	Microsoft Word[removed]VIOL Zevalin Notice of Violation Letter1.doc Add to Reading List Source URL: www.fda.gov Language: English Ibritumomab tiuxetan Biogen Idec Rituximab Boxed warning Adverse effect Food and Drug Administration Spectrum Pharmaceuticals Medicine Pharmaceutical sciences Pharmacology
149	Abstract # 2750 Pharmacokinetic and Pharmacodynamic Analysis of Ocaratuzumab in 50 Patients with Relapsed Follicular Lymphoma and Low-Affinity FcRIIIa (CD16a) Polymorphisms M Du, A O’Reilly, P Le, V Jain Add to Reading List Source URL: www.mentrik.com Language: English - Date: 2012-12-06 17:52:51 CD20 Pharmacokinetics Lymphoma Pharmacology Pharmaceutical sciences Rituximab
150	Immunomedics Inc. Logo_PMS[removed] Add to Reading List Source URL: www.immunomedics.com Language: English - Date: 2014-04-30 11:51:05 Immune system Monoclonal antibodies Orphan drugs Immunology Cancer immunotherapy B-cell chronic lymphocytic leukemia Humanized antibody Prostate cancer Rituximab Medicine Anatomy Health